adamantane has been researched along with uracil in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (5.56) | 29.6817 |
| 2010's | 47 (87.04) | 24.3611 |
| 2020's | 4 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejewska, M; Górska, A; Kamiński, J; Kazimierezuk, Z | 1 |
| Gwaltney, SL | 1 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Cefalu, WT | 1 |
| Kuritzky, L | 1 |
| Scheen, AJ | 2 |
| Gerich, J | 1 |
| Boudes, P; Viereck, C | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Itoh, H; Saisho, Y | 1 |
| Bakris, GL; Flynn, C | 1 |
| Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Cohen, D | 1 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Mitka, M | 1 |
| Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T | 1 |
| Standl, E | 1 |
| Tibaldi, JM | 1 |
| Mullard, A | 1 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Davis, TM | 2 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Gallwitz, B; Nitschmann, S | 1 |
| Clifton, P | 1 |
| Dicembrini, I; Mannucci, E | 1 |
| Burciu, C; Koska, J; Reaven, P; Sands, M | 1 |
| Hirshberg, B; Katz, A | 1 |
| Bhamidipati, RK; Gilibili, RR; Mullangi, R; Srinivas, NR | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Baker, WL; White, WB | 1 |
| Jermendy, G | 1 |
| Cahn, A; Raz, I; Schernthaner, G | 1 |
| Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A | 1 |
| Raz, I; Tkáč, I | 1 |
| Hernández, C; Simó, R | 1 |
| Arao, T; Hajime, M; Kuno, F; Kurozumi, A; Mine, S; Miyazaki, M; Mori, H; Narisawa, M; Okada, Y; Sonoda, S; Sugai, K; Tanaka, K; Tanaka, Y; Torimoto, K | 1 |
| Mannucci, E; Monami, M | 1 |
| Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y | 2 |
| Lingvay, I | 1 |
| Kaneko, M; Narukawa, M | 1 |
| Abeni, D; Collina, MC; Di Zenzo, G; Didona, B; Fania, L; Mazzanti, C; Pagnanelli, G; Provini, A; Salemme, A | 1 |
| Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB | 1 |
| Cheng, CY; Chiang, CP; Chien, WC; Chung, CH; Hung, CT; Liu, JS; Wang, WM | 1 |
| Dicembrini, I; Mannucci, E; Monami, M; Montereggi, C; Nreu, B | 1 |
| Hardman, TC; Hucke, O; Klein, T; Nar, H; Schnapp, G | 1 |
| Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
26 review(s) available for adamantane and uracil
| Article | Year |
|---|---|
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Topics: Adamantane; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2008 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Piperidines; Renal Insufficiency; Risk Factors; Treatment Outcome; Uracil | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Nitriles; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2014 |
Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Myocardial Infarction; Patient Outcome Assessment; Patient Selection; Piperidines; Research Design; Time Factors; Uracil | 2015 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Topics: Adamantane; Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incretins; Piperidines; Protective Factors; Risk Assessment; Risk Factors; Treatment Outcome; Uracil | 2015 |
Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Piperidines; Sitagliptin Phosphate; Treatment Outcome; Uracil | 2015 |
[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Sitagliptin Phosphate; Uracil | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil | 2016 |
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Uracil | 2016 |
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.
Topics: Acute Disease; Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Pancreatitis; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil | 2017 |
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Meta-Analysis as Topic; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incidence; Neoplasms; Piperidines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Uracil; Vildagliptin | 2020 |
2 trial(s) available for adamantane and uracil
| Article | Year |
|---|---|
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
27 other study(ies) available for adamantane and uracil
| Article | Year |
|---|---|
Microwave-assisted synthesis of O'-adamantylated uracil-derived nucleosides.
Topics: Adamantane; Deoxyuridine; Hot Temperature; HSP70 Heat-Shock Proteins; Microwaves; Molecular Chaperones; Nucleosides; Saccharomyces cerevisiae Proteins; Thymidine; Uracil; Zidovudine | 2003 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
Topics: Adamantane; Aged; Angioedema; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Substitution; Humans; Male; Nitriles; Piperidines; Pyrrolidines; Uracil; Vildagliptin | 2013 |
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction | 2013 |
New oral hypoglycaemics fail to show cardiovascular benefits.
Topics: Adamantane; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Randomized Controlled Trials as Topic; Treatment Failure; Uracil | 2013 |
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2013 |
Pharmacoeconomic analysis of DPP-4 inhibitors.
Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Outcome results renew debate about diabetes drug development.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Treatment Outcome; Uracil | 2013 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Topics: Adamantane; Administration, Intravenous; Administration, Oral; Animals; Biphenyl Compounds; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Haplorhini; Humans; Nitriles; Piperidines; Prospective Studies; Pyridines; Pyrrolidines; Quinolizines; Rats; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2015 |
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Risk Factors; Sitagliptin Phosphate; Uracil | 2016 |
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Uracil; Vildagliptin | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil | 2016 |
Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Topics: Adamantane; Algorithms; Area Under Curve; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrrolidines; Treatment Outcome; Uracil; Vildagliptin | 2017 |
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Hospitalization; Humans; Piperidines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Sitagliptin Phosphate; Uracil | 2017 |
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Autoantibodies; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Epitopes; Female; Humans; Immunoglobulin A; Immunoglobulin E; Immunoglobulin G; Linagliptin; Male; Membrane Glycoproteins; Middle Aged; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2018 |
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Ligands; Liraglutide; Models, Molecular; Molecular Targeted Therapy; Nitriles; Peptides; Piperidines; Pyrrolidines; Reproducibility of Results; Sitagliptin Phosphate; Uracil; Venoms; Vildagliptin | 2018 |
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Linagliptin; Male; Middle Aged; Piperidines; Practice Guidelines as Topic; Sitagliptin Phosphate; United States; United States Food and Drug Administration; Uracil | 2018 |
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Topics: Adamantane; Adult; Age Factors; Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Linagliptin; Male; Middle Aged; Pemphigoid, Bullous; Piperidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Uracil; Vildagliptin; Young Adult | 2020 |
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
Topics: Adamantane; Antiviral Agents; Coronavirus 3C Proteases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Repositioning; Enzyme Assays; Heterocyclic Compounds; Linagliptin; Piperidines; SARS-CoV-2; Sitagliptin Phosphate; Uracil | 2021 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |